Lynne K Garrity-Ryan

Summary

Affiliation: Paratek Pharmaceuticals
Country: USA

Publications

  1. pmc Small molecule inhibitors of LcrF, a Yersinia pseudotuberculosis transcription factor, attenuate virulence and limit infection in a murine pneumonia model
    Lynne K Garrity-Ryan
    Paratek Pharmaceuticals, Inc, Boston, MA 02111, USA
    Infect Immun 78:4683-90. 2010
  2. pmc N-hydroxybenzimidazole inhibitors of the transcription factor LcrF in Yersinia: novel antivirulence agents
    Oak K Kim
    Paratek Pharmaceuticals, Inc, 75 Kneeland Street, Boston, Massachusetts 02111, USA
    J Med Chem 52:5626-34. 2009
  3. doi request reprint N-Hydroxybenzimidazole inhibitors of ExsA MAR transcription factor in Pseudomonas aeruginosa: In vitro anti-virulence activity and metabolic stability
    Mark C Grier
    Paratek Pharmaceuticals, Inc 75 Kneeland Street, Boston, MA 02111, USA
    Bioorg Med Chem Lett 20:3380-3. 2010
  4. ncbi request reprint MarA, SoxS and Rob function as virulence factors in an Escherichia coli murine model of ascending pyelonephritis
    Paul Casaz
    Paratek Pharmaceuticals, Inc, 75 Kneeland Street, Boston, MA 02111, USA
    Microbiology 152:3643-50. 2006
  5. pmc In vitro and in vivo antimalarial efficacies of optimized tetracyclines
    Michael P Draper
    Paratek Pharmaceuticals, Inc, Boston, Massachusetts, USA
    Antimicrob Agents Chemother 57:3131-6. 2013

Collaborators

  • Michael N Alekshun
  • Stuart Levy
  • Oak K Kim
  • JOAN C MECSAS
  • Michael P Draper
  • Mark C Grier
  • S Ken Tanaka
  • Paul Casaz
  • Kevin Klausner
  • Aleksandrs Odinecs
  • Kwasi Ohemeng
  • Janice Donatelli
  • Laura Honeyman
  • Kelley Larson
  • Raina G Leahy
  • Philip J Rosenthal
  • Jiri Gut
  • Ann Macone
  • Mark L Nelson
  • Haregewein Assefa
  • Atul K Verma
  • Beena Bhatia
  • Kevin A Klausner
  • Peter J Donovan
  • Caroline Dudley
  • Victoria J Bartlett
  • Caroline Jackson
  • David McKenney

Detail Information

Publications5

  1. pmc Small molecule inhibitors of LcrF, a Yersinia pseudotuberculosis transcription factor, attenuate virulence and limit infection in a murine pneumonia model
    Lynne K Garrity-Ryan
    Paratek Pharmaceuticals, Inc, Boston, MA 02111, USA
    Infect Immun 78:4683-90. 2010
    ..The MAR family of transcription factors is well conserved, with members playing central roles in pathogenesis across bacterial genera; thus, the inhibitors could have broad applicability...
  2. pmc N-hydroxybenzimidazole inhibitors of the transcription factor LcrF in Yersinia: novel antivirulence agents
    Oak K Kim
    Paratek Pharmaceuticals, Inc, 75 Kneeland Street, Boston, Massachusetts 02111, USA
    J Med Chem 52:5626-34. 2009
    ..These results demonstrate that N-hydroxybenzimidazole inhibitors, exemplified by 14, 22, and 36, are effective antivirulence agents and have the potential to prevent infections caused by Yersinia spp...
  3. doi request reprint N-Hydroxybenzimidazole inhibitors of ExsA MAR transcription factor in Pseudomonas aeruginosa: In vitro anti-virulence activity and metabolic stability
    Mark C Grier
    Paratek Pharmaceuticals, Inc 75 Kneeland Street, Boston, MA 02111, USA
    Bioorg Med Chem Lett 20:3380-3. 2010
    ..aeruginosa was demonstrated in a whole cell assay. Select N-hydroxybenzimidazole inhibitors were stable in an in vitro human liver microsomal assay...
  4. ncbi request reprint MarA, SoxS and Rob function as virulence factors in an Escherichia coli murine model of ascending pyelonephritis
    Paul Casaz
    Paratek Pharmaceuticals, Inc, 75 Kneeland Street, Boston, MA 02111, USA
    Microbiology 152:3643-50. 2006
    ..Deletion of soxS or rob alone was more detrimental than the removal of marA. Thus, all three proteins contribute to virulence in vivo...
  5. pmc In vitro and in vivo antimalarial efficacies of optimized tetracyclines
    Michael P Draper
    Paratek Pharmaceuticals, Inc, Boston, Massachusetts, USA
    Antimicrob Agents Chemother 57:3131-6. 2013
    ..Optimized compounds may allow lower doses for treatment and chemoprophylaxis. If safety margins are adequate, dosing in children, the group at greatest risk for malaria in countries in which it is endemic, may be feasible...